Regulatory Submission

You’ve spent years developing your device. The engineering is sound. The clinical evidence is compelling. And now it sits in a regulatory queue somewhere, waiting for someone you have never met to decide its fate.

Here’s an uncomfortable statistic: almost one-third of submissions fail the initial acceptance review. These fell by the wayside because someone forgot a section, mislabelled a document, or failed to cross-reference properly. These are not bad devices. They are bad applications.

In the UK and Europe, the landscape is shifting dramatically. The MHRA is streamlining pathways for innovative technologies, while the EU continues to refine the Medical Device Regulation (MDR) framework. Both jurisdictions are signalling the same message: come prepared, or do not come at all.

Why submissions fail

Regulatory reviewers are not your adversaries. They are professionals drowning in paperwork, under pressure to protect patients while enabling innovation. When your submission lands on their desk, you have seconds to make a first impression.
The most common failures are devastatingly simple. Incomplete documentation. Missing test data. Vague clinical justifications. Incorrect pathway selection. Each mistake triggers a cycle of additional information requests, delays, and mounting costs. A 2024 MedTech Europe survey found that over half of conformity assessment time is spent outside the actual review phase, consumed instead by administrative back-and-forth.

Think about that. More than half the time is lost to preventable friction.

The pathway question

Before you write a single word of your submission, you need absolute certainty about your regulatory pathway. This is not a decision to delegate or rush.
In the UK, the MHRA is introducing international reliance routes that will allow devices already approved by the FDA, Health Canada, or Australia's TGA to follow a streamlined pathway to market. This fundamentally changes the strategic calculus for global innovators.

The proposed changes to the regulations represent the most significant advances since their original introduction. When enacted, we will lead the world in streamlining medical device approvals.

_{Professor Tom Clutton-Brock. Chair of the MHRA's Interim Devices Working Group}

For the EU, the path remains more complex. The MDR requires comprehensive technical documentation, robust clinical evidence, and engagement with a notified body. Classification matters enormously. A Class I device faces different requirements than a Class III implantable. Getting this wrong at the outset will cascade down through every subsequent decision.

Building a bulletproof submission

Think like a reviewer. This is not just advice; it is a survival strategy. Your submission is a story. It needs a clear beginning, middle, and end. The reviewer should never have to hunt for information or wonder how one section connects to another. Executive summaries matter. Clear headings matter. Logical cross-referencing matters.

So, start with your device description. Be precise. Be complete. Explain what it does, how it works, and what makes it different from predicate devices or existing solutions. Ambiguity here creates questions everywhere else. Your clinical evidence needs to be compelling and clearly presented. This does not mean overwhelming the reviewer with data. It means presenting the right data, organised thoughtfully, with clear conclusions. If your device requires clinical studies, ensure they’re designed to address the specific questions regulators will ask. If you are relying on literature, curate it carefully and explain its relevance.
Standards conformity is non-negotiable. You should aim to demonstrate compliance with all relevant standards and guidance, whether that is ISO 13485 for quality management, IEC 60601 for electrical safety, or biocompatibility standards. Do not assume the reviewer knows you have done this work. Prove it explicitly.

One of Europe's many strengths is its unrivalled innovation creation. The medical technology sector in Europe files a patent every 30 minutes. The risk-adverse nature of EU policies can lead to overregulation, or unfitted regulation.

_{Oliver Bisazza, CEO of MedTech Europe}

For innovators, this means one thing: your EU submission needs to be impeccable. There’s less margin for error than ever before.

Preparing for questions

Every submission generates questions. The goal is not to avoid questions entirely but to minimise unnecessary ones and respond swiftly when they arrive. So, aim to build a rapid response team before you submit. Identify who will handle clinical queries, engineering questions, and quality system clarifications. Pre-draft responses to likely questions based on your own review of the submission. When a request arrives, respond promptly and completely. Partial answers or delayed responses signal disorganisation and erode confidence.

The hidden advantage

Here is what most innovators miss: regulatory excellence is a competitive advantage, not just a compliance burden. Companies that invest in a robust regulatory strategy move faster. They face fewer delays, lower costs, and reach patients sooner. In a market where first-mover advantage can define success, the ability to navigate regulatory pathways efficiently is as valuable as any technical breakthrough. The MHRA approved 84 clinical investigations for new medical devices in 2024 alone. The pathway exists for innovators who are prepared. The question is whether your submission will be one of them.

Regulatory submissions workshop

Regulatory submission is where preparation meets opportunity. Every hour you invest in getting your documentation right, in thinking like a reviewer, in anticipating questions before they are asked, pays dividends when it matters most. Together with the team at VP Med Ventures, we can help you prepare the perfect paper. Fine-tune your story. And make sure your submission hits the right note with reviewers. Your device deserves the best possible chance.

Waypoint checklist

A considered reminder for your submission:

• Check you’re pursuing the correct regulatory pathway for your device.
• Ensure all required sections and supporting data are complete and accurate.
• Present clear and convincing clinical evidence if necessary.
• Demonstrate conformity to all relevant standards and guidance.
• Be prepared to respond promptly to questions from regulatory reviewers.
• Think like a reviewer. Organise your submission logically, use clear headings and cross-references, and provide executive summaries for complex sections.